- Home
- IRS vs ANAB Comparison
IRS vs ANAB Comparison
Compare IRS & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRS
- ANAB
- Stock Information
- Founded
- IRS 1943
- ANAB 2005
- Country
- IRS Argentina
- ANAB United States
- Employees
- IRS N/A
- ANAB N/A
- Industry
- IRS Homebuilding
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- IRS Real Estate
- ANAB Health Care
- Exchange
- IRS Nasdaq
- ANAB Nasdaq
- Market Cap
- IRS 873.6M
- ANAB 759.5M
- IPO Year
- IRS 1994
- ANAB 2017
- Fundamental
- Price
- IRS $14.62
- ANAB $19.94
- Analyst Decision
- IRS Strong Buy
- ANAB Buy
- Analyst Count
- IRS 1
- ANAB 9
- Target Price
- IRS $12.62
- ANAB $34.86
- AVG Volume (30 Days)
- IRS 148.1K
- ANAB 848.5K
- Earning Date
- IRS 05-06-2025
- ANAB 05-08-2025
- Dividend Yield
- IRS 11.32%
- ANAB N/A
- EPS Growth
- IRS N/A
- ANAB N/A
- EPS
- IRS N/A
- ANAB N/A
- Revenue
- IRS $325,094,048.00
- ANAB $91,280,000.00
- Revenue This Year
- IRS N/A
- ANAB N/A
- Revenue Next Year
- IRS N/A
- ANAB $37.76
- P/E Ratio
- IRS N/A
- ANAB N/A
- Revenue Growth
- IRS N/A
- ANAB 432.03
- 52 Week Low
- IRS $8.21
- ANAB $12.21
- 52 Week High
- IRS $17.67
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- IRS 55.31
- ANAB 58.61
- Support Level
- IRS $13.63
- ANAB $15.40
- Resistance Level
- IRS $14.65
- ANAB $22.29
- Average True Range (ATR)
- IRS 0.99
- ANAB 1.43
- MACD
- IRS 0.18
- ANAB 0.27
- Stochastic Oscillator
- IRS 81.38
- ANAB 68.21
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).